News
ATX-559, a first-in-class oral DHX9 inhibitor, is being evaluated in a Phase 1/2 study with a focuson advanced or metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback